The challenge
Inbeeo’s client, a leading CNS-focused company, is looking to expand their current non-orphan portfolio with a number of orphan drugs.
Given the client has had limited experience in launching orphan drugs, they required a more detailed understanding of the HTA, pricing and market access environment in Australia, to inform their access strategy.
A key priority for them was to understand the potential for early and alternative access pathways which may be available, and to establish the viability of each of these for the client’s current pipeline products.
The approach
Following a review of the Australian landscape, Inbeeo produced an in-depth report detailing the HTA, pricing and market access processes. For pathways that were more relevant for orphan drugs, specific focus was put on eligibility criteria and processes.
The research was validated through primary research with experts in the Australian system. Inbeeo also worked with the experts to identify key orphan drug analogues for further review, which provided context for how the processes were implemented in the real world. Key insights and targeted recommendations were extracted.
The impact
Key insights and recommendations from Inbeeo, informed by landscape and analogue analyses, were used by the global market access team to enable early planning of the Australian access strategy. A key deliverable was the development of a roadmap designed to facilitate rapid access to the client’s products.
